Esperion Therapeutics Stock Discussion

Youngman : Right. It should at 4 dollars by now

SuIIIIT :

Fortune Smiles 88 : I agree. Low risk high gain opportunity. Retail price for one month nexletol/nexlizer cost $400 per patient. Assuming just 1m patients in USA alone, will net Esperian gross sales of $400m a months or close to half a billion annually. Extrapolate it to global population. Potential is immense.

Youngman : Let's go!

HH1000 : what are you talking about?

StockAmateur OP : if you pay attention to the chart, every time it goes to resistance area. It always stopped with a flat high and being forced to go lower, it happens so many times already

HH1000 : no...it's Powell's speech.  the entire market dropped.

StockAmateur HH1000 : ban him from speech

比特币骗子勿扰 : Fool, when others rise, you drop proactively, now that others have fallen, just follow the fall. Let's see how much you can drop!

72792912 OP : In my opinion, the profit potential of this stock is not large.

72792912 OP 比特币骗子勿扰 : I will basically no longer buy pharmaceutical stocks in the future because the risk is too high.

比特币骗子勿扰 72792912 OP : This stock is being manipulated heavily.

72792912 OP : Yes.

Youngman : Seems like every time they mention something about their financing  some people get spooked  lol

StockAmateur : what's your entry? I'm at 2.370.. kinda worry now

StockAmateur OP : ### Key Points:
1. **Debt Restructuring**:  
  Esperion has implemented a significant debt restructuring plan:
  - Closed a **$150 million senior secured term loan** led by Athyrium Capital Management and joined by HealthCare Royalty.
  - Issued **$100 million convertible notes** to repay $210 million of the existing $265 million convertible debt.
  - Remaining funds will be used as operating cash.
2. **Strategic Investors**:  
  The financing is supported by specialized healthcare investors (Athyrium and HCRx), reflecting confidence in Esperion's long-term growth and commercialization efforts.
3. **Extended Debt Maturity**:  
  The new debt has a repayment schedule delayed by five years or more, giving the company more financial flexibility.
4. **Focus on Core Products**:  
  The funds will support the development and commercialization of **NEXLETOL** and **NEXLIZET**, medications targeting cardiovascular diseases.
5. **Interest Rates**:  
  - The $150M loan bears interest at **9.75% (cash)** or **11.75% (paid in-kind)**.  
  - Convertible notes carry a **5.75% annual interest** and mature in 2030.
6. **Market Confidence**:  
  Statements from leadership and investors emphasize the restructuring as a step to ensure long-term growth and stability.
---
### Impact on Stock Price:
- **Positive Indicators**:
 - Resolving 80% of existing debt is a significant financial improvement, potentially seen as positive by investors.
 - Support from reputable healthcare investors boosts credibility.
 - Focused investment in commercializing products aligns with long-term revenue growth.
- **Potential Risks**:
 - High-interest rates on new debt could pressure future earnings.
 - Convertible notes could dilute equity if converted into shares.
 - Market sentiment may depend on the commercial success of their core products (NEXLETOL and NEXLIZET).